Skip to main content

CV

Curriculum vitae — positions, education, research, publications and presentations.

Download as PDF

Neurologist and quantitative researcher combining clinical neurology with real-world evidence methods in ALS. National data manager for the Spanish ALS Registry and active investigator across industry-sponsored trials; focused on the intersection of registry science, biostatistics, and regulatory-grade evidence generation.

Professional experience

  • Apr 2025–present
    National ALS Registry of Spain
    National Data Manager Mar 2026–present
    Data Manager Apr 2025–Nov 2025
  • Feb 2024–present
    Bellvitge Biomedical Research Institute (IDIBELL)
    Clinical Researcher
  • May 2019–present
    Bellvitge University Hospital
    Neurologist Jun 2023–present
    Neurology Resident May 2019–May 2023

Education

  • In progress
    PhD in Medicine and Translational Research
    Universitat de Barcelona (UB)
  • In progress
    University Master's Degree in Data Science
    Universitat Oberta de Catalunya (UOC) · 60 ECTS + 60 ECTS bridging courses
  • Oct 2025
    University Expert Diploma in Comprehensive Training and Management of Spinal Muscular Atrophy (SMA)
    Universidad Europea de Madrid (UEM) · 6 ECTS
  • Apr 2025
    Postgraduate Master's in Neuroimmunology
    Universitat Autònoma de Barcelona · 60 ECTS
  • Jan 2023
    Postgraduate Master's in Clinical Neurology
    Universidad Francisco de Vitoria · Sociedad Española de Neurología · 90 ECTS
  • Nov 2022
    Postgraduate Diploma in Clinical Medicine
    Universidad a Distancia de Madrid (UDIMA)
  • Jun 2018
    Degree in Medicine
    Universitat de València · 360 ECTS

Medical specialty

  • May 2019–May 2023
    Neurology
    Bellvitge University Hospital · Barcelona, Spain · 4 years

Certifications and training

Good Clinical Practice

  • Jul 2025
    ICH Good Clinical Practice E6(R3)
    The Global Health Network
  • Dec 2022
    ICH Good Clinical Practice E6(R2)
    The Global Health Network

Regulatory affairs

  • Jul 2026
    Introduction to Regulatory Affairs
    European Patients' Academy on Therapeutic Innovation (EUPATI)

ALS assessment scales

  • Apr 2026
    TRICALS Risk Score valid until Apr 2028
    TRICALS
  • Dec 2022
    Harmonized ALSFRS-R valid until Jul 2027
    TRICALS
  • Dec 2022
    ALS King's Staging
    TRICALS
  • Dec 2022
    Edinburgh Cognitive and Behavioural ALS Screen (ECAS)
    University of Edinburgh

Respiratory, motor and speech assessment

  • Apr 2024
    Isometric Strength Testing (hand-held dynamometry) valid until Feb 2028
    TRICALS
  • Jan 2023
    Slow Vital Capacity (SVC) valid until Feb 2028
    TRICALS

Safety assessment

  • Apr 2023
    C-SSRS Training (Spanish-Spain, V1.2) valid until Jul 2027
    Research Foundation for Mental Hygiene

Movement-disorder scales

  • Nov 2022
    UHDRS Motor Rater Training
    International Parkinson and Movement Disorder Society
  • Nov 2021
    MDS-UPDRS Training Program
    International Parkinson and Movement Disorder Society
  • Nov 2021
    Unified Dyskinesia Rating Scale Training
    International Parkinson and Movement Disorder Society

Data analysis

  • Jun 2022
    Google Data Analytics
    Google

Clinical trials

  • Jul 2026–present
    Ongoing
    PREVAiLS — Pridopidine in amyotrophic lateral sclerosis
    Prilenia Therapeutics, Ferrer · Phase III · NCT07322003 · EU CT 2025-524002-16-00
    Sub-investigator
  • Apr 2026–present
    Ongoing
    OWAA — A Multiple Ascending Dose Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally Administered LY4256984 in Participants with Sporadic Amyotrophic Lateral Sclerosis
    Eli Lilly and Company · Phase I · NCT07100119 · EU CT 2025-521295-60-00
    Sub-investigator
  • Jul 2025–present
    Ongoing
    ASTRALS — A phase 2, randomized, double-blind, placebo-controlled parallel group study of VHB937 in ALS over 40 weeks followed by an Open-label Extension
    Novartis Farmacéutica, S.A. · Phase II · NCT06643481 · EU CT 2024-512536-29-00
    Sub-investigator
  • Jun 2021–present
    Ongoing
    FUS-ALS — A Phase 1-3 Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION363 in Amyotrophic Lateral Sclerosis Patients With Fused in Sarcoma Mutations
    Ionis Pharmaceuticals, Inc. · Phase I-III · NCT04768972 · EudraCT 2020-005522-28
    Principal investigator (May 2026–present) · Sub-investigator (Jun 2021–Apr 2026)
  • Nov 2022–Sep 2025
    Finalized
    MAGNET — Multi-arm, Adaptive, Group-sequential trial NETwork — Lithium Substudy
    TRICALS Consortium · Phase III · NCT06008249 · EudraCT 2020-000579-19
    Sub-investigator

Research projects

  • 2023–present
    Ongoing
    PRECISION-ALS — Prospective pan-European study of ALS using an integrated patient data platform
    Biogen, IQVIA, Novartis, TRICALS Consortium
  • 2024–2026
    Ongoing
    SEED-ALS — Synergizing Efforts to Develop and Accelerate Breakthroughs in ALS Research
    Instituto de Salud Carlos III (ISCIII)
  • Feb 2024–present
    Ongoing
    Epidemiological study of ALS in Colombia and Ethiopia
    ALS Society of Canada
  • 2023
    Cáncer de pulmón y toxicidad cognitiva: marcadores serológicos y de neuroimagen de disrupción de la barrera hematoencefálica
    Instituto de Salud Carlos III (ISCIII)

Externships & Research Stays

  • Jan 2025–Mar 2025
    Trinity College Dublin
    Dublin, Ireland
    Doctoral research
  • Sep 2022–Oct 2022
    Maurice Wöhl Clinical Neuroscience Institute
    King's College London · London, United Kingdom
    External rotation in bioinformatics and ALS
  • Apr 2022–May 2022
    Vall d'Hebron University Hospital
    Barcelona, Spain
    External rotation in paediatric neurology

Grants and scholarships

  • Jul 2024
    7th Neuromuscular Diseases Rotation Grant
    Spanish Society of Neurology · 3 months
    Trinity College Dublin

Awards

  • May 2024
    Best clinical scientific poster presentation
    Fundación Francisco Luzón · Madrid, Spain